<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26783">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963715</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN0501</org_study_id>
    <nct_id>NCT01963715</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors</brief_title>
  <official_title>A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first-in-human  study to determine the recommended dose of IMGN289 in
      adult patients with advanced EGFR-positive tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the amount of IMGN289 in participants blood (pharmacokinetics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of IMGN289</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the amount of IMGN289 in participants blood (pharmacokinetics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Human Anti Human Antibody and Human Anti Drug Antibody</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess whether participants develop an immune response to IMGN289</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor measurements per RECIST 1:1</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess preliminary anti-tumor activity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>EGFR Positive Solid Tumors</condition>
  <arm_group>
    <arm_group_label>EGFR+ Solid Tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR+ Solid Tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMGN289</intervention_name>
    <arm_group_label>EGFR+ Solid Tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old at time of consent

          -  Diagnosed with a solid tumor that has progressed despite standard therapy or     for
             which no standard effective or curative options exist or are suitable

          -  EGFR-positive tumor expression

          -  Adequate blood and organ function

          -  Must agree to use contraception while on study and for 12 weeks after the last dose
             of IMGN289 as applicable

          -  Must be willing and able to sign informed consent and follow the study schedule and
             other protocol requirements

        Exclusion Criteria:

          -  Other anti-cancer treatment during the study

          -  Symptomatic brain metastases

          -  Other clinically significant disease as defined by the protocol

          -  Chronic skin condition that requires prescribed oral or intravenous treatment

          -  History of severe rash that required discontinuation of prior EGFR targeted therapy

          -  Receiving therapeutic doses of warfarin or heparin for anti-coagulation

          -  Known diagnosis of HIV or active viral hepatitis

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Vergara-Silva, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Vergara-Silva, MD</last_name>
    <phone>781-895-0600</phone>
    <email>imgn0501trial@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Bryant</last_name>
      <phone>310-248-6735</phone>
      <email>miranda.bryant@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Alain C Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra West</last_name>
      <email>swest8@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Hyunseok Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudo Makonza-Goto</last_name>
      <phone>617-632-6284</phone>
      <email>rudo_makonzagoto@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Leena Gandhi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Wolfe</last_name>
      <phone>313-576-9365</phone>
      <email>wolfea@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Patricia M LoRusso, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMGN289</keyword>
  <keyword>Antibody Drug Conjugate</keyword>
  <keyword>antibody</keyword>
  <keyword>EGFR</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>Head and neck</keyword>
  <keyword>Squamous cell carcinoma</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Immunogen</keyword>
  <keyword>Lung</keyword>
  <keyword>Phase 1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
